Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

v3.21.1
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
Preferred Stock
Common Stock
Private Placement
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Income/(Loss)
Accumulated Deficit
Total
Balance at Dec. 31, 2019 $ 41   $ 40,778 $ 106,689,065 $ 139,465 $ (100,246,894) $ 6,622,455
Balance (in shares) at Dec. 31, 2019 4,092   4,077,755        
Stock-Based Compensation       145,920     145,920
Issuance of Common Stock in Offerings, Net of Offering Costs     $ 5,000 4,496,313     4,501,313
Issuance of Common Stock in Offerings, Net of Offering Costs (in shares)     500,000        
Issuance of Common Stock from Restricted Stock Award Grants     $ 490 (490)      
Issuance of Common Stock from Restricted Stock Award Grants (in shares)     49,000        
Foreign Currency Translation Adjustment         188   188
Net Loss           (1,952,200) (1,952,200)
Balance at Mar. 31, 2020 $ 41   $ 46,268 111,330,808 139,653 (102,199,094) 9,317,676
Balance (in shares) at Mar. 31, 2020 4,092   4,626,755        
Balance at Dec. 31, 2020 $ 41   $ 55,564 115,283,572 (802) (108,338,834) 6,999,541
Balance (in shares) at Dec. 31, 2020 4,138   5,556,394        
Stock-Based Compensation       216,945     216,945
Issuance of Common Stock in Offerings, Net of Offering Costs   $ 15,311   7,973,550     7,988,861
Issuance of Common Stock in Offerings, Net of Offering Costs (in shares)   1,531,101          
Issuance of Shares of Common Stock from Warrant Exercises     $ 104 49,897     50,001
Issuance of Shares of Common Stock from Warrant Exercises (in shares)     10,417        
Foreign Currency Translation Adjustment         10,473   10,473
Net Loss           (2,580,821) (2,580,821)
Balance at Mar. 31, 2021 $ 41   $ 70,979 $ 123,523,694 $ 9,671 $ (110,919,655) $ 12,685,000
Balance (in shares) at Mar. 31, 2021 4,138   7,097,912